In breast cancer, ARPC2 expression significantly upregulated the expression of vimentin, N-cadherin, MMP-9, ZEB1, and MMP-3, activated the TGF-β pathway, and eventually led to epithelial–mesenchymal transition (EMT) (Cheng et al., 2019). Here, ARPC2 is linked to breast carcinoma.